Resistance to checkpoint blockade therapy

Patent metadata

Field	Value
Publication number	US-11634777-B2
Application number	US-201816477827-A
Country	US
Kind code	B2
Filing date	Jan 12, 2018
Priority date	Jan 13, 2017
Publication date	Apr 25, 2023
Grant date	Apr 25, 2023

Abstract

Provided herein are methods of determining resistance to checkpoint blockade (CPB) therapy in a cancer patient, methods of typing tumor cells of a cancer patient, methods of assigning treatment to a cancer patient and methods of treatment of a cancer patient based on determining in a tumor sample of said patient, reduced expression of a gene relating to antigen processing pathway or a product thereof, or a modification causing said reduced expression, wherein the presence of said reduced expression or modification is indicative of resistance to CPB therapy.

First claim

What is claimed is:

1. A method for treating cancer in a patient resistant to CPB therapy, said method comprising:
detecting, in a tumor sample from the patient, one or more genetic modifications in the B2M gene, wherein the one or more genetic modifications are selected from the group consisting of: the combination of a p.Leu13fs and p.Ser14fs frame-shift mutation, the combination of a p.Gly63fs and p.Ser14fs frame-shift mutation, a p.Leu13fs frame-shift mutation, and a p.Gly63fs frame-shift mutation;
treating the patient with a CPB therapy if the one or more genetic modifications are not detected, or treating the patient with a therapy other than CPB therapy if the one or more genetic modifications are detected.

2. The method of claim 1 , further comprising detecting a mutation or deletion in chromosome 15, wherein the mutation or deletion results in loss of heterozygosity (LOH) of the beta-2-microglobulin (B2M) gene.

3. The method of claim 1 , wherein said sample is a blood sample or tumor biopsy sample.

4. The method of claim 1 , wherein the cancer is a melanoma.

5. The method of claim 1 , wherein the genetic modification is detected by sequencing, optionally, wherein sequencing comprises whole exome sequencing.

6. The method of claim 1 , wherein the patient has not received CPB therapy; or
wherein the patient is receiving CPB therapy; or
wherein the patient has relapsed after receiving CPB therapy.

7. The method of claim 1 , wherein said CPB therapy comprises treatment with anti-CTLA4, anti-PD1, anti-PDL1 antibodies or a combination thereof.

8. The method of claim 1 , wherein the therapy other than CPB therapy is selected from the group consisting of NK cell therapy, radiotherapy, chemotherapy, and tumor-specific monoclonal antibodies, optionally, wherein said NK cell therapy is an adoptive NK cell therapy and/or treatment with an agonistic antibody directed against an NK cell receptor, or wherein the agonistic antibody is selected from anti-CD137, anti-CD27, and anti-OX40.

9. The method of claim 1 , further comprising restoring the genetic modification in the B2M gene using gene therapy.

10. A method for treating cancer in a patient resistant to CPB therapy, said method comprising:
staining a tumor sample from the patient for B2M protein and one or more markers specific to tumor cells;
determining the expression of B2M protein based on B2M staining in tumor cells stained by the one or more markers specific to tumor cells, wherein the B2M expression is scored based on the percentage of B2M expressing cells in the tumor fraction, such that Minimal is 0-10%; Low is 10-50%; Intermediate is 50-80%; and High is 80-100%; and
treating the patient with a CPB therapy if B2M expression is Low, Intermediate, or High, or treating the patient with a therapy other than CPB therapy if B2M is Minimal.

11. The method of claim 10 , wherein the cancer is a melanoma; or
wherein the patient has not received CPB therapy; or
wherein the patient is receiving CPB therapy; or
wherein the patient has relapsed after receiving CPB therapy; or
wherein said CPB therapy comprises treatment with anti-CTLA4, anti-PD1, anti-PDL1 antibodies or a combination thereof; or
wherein the therapy other than CPB therapy is selected from the group consisting of NK cell therapy, radiotherapy, chemotherapy, and tumor-specific monoclonal antibodies, optionally, wherein said NK cell therapy is an adoptive NK cell therapy and/or treatment with an agonistic antibody directed against an NK cell receptor, or wherein the agonistic antibody is selected from anti-CD137, anti-CD27, and anti-OX40; or
wherein said sample is a tumor biopsy sample.

12. The method of claim 1 , wherein the one or more genetic modifications are detected in cell-free DNA isolated from a blood sample from the patient.

Assignees

• Massachusetts Gen Hospital

Inventors

• Hacohen Nir
• Sade-Feldman Moshe

Classifications

• C07K16/2878

  against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C07K16/2827

  against B7 molecules, e.g. CD80, CD86 · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title